Outlook Therapeutics Business Summary

Outlook Therapeutics, Inc. (OTLK) is a commercial-stage biopharmaceutical company specializing in the development and monetization of ONS-5010 (LYTENAVA), the first approved ophthalmic formulation of bevacizumab for retinal diseases. The company generates revenue through the direct commercial sale of LYTENAVA in authorized European markets, including Germany, the United Kingdom, and Austria, as well as through strategic licensing and exclusive distribution agreements, such as its 2026 partnership with Mediconsult AG in Switzerland. Its primary business segment is the commercialization of anti-VEGF therapies designed to replace the prevalent off-label use of intravenous bevacizumab in treating wet age-related macular degeneration (wet AMD). Outlook Therapeutics competes directly with industry giants such as Regeneron Pharmaceuticals (Eylea), Roche/Genentech (Lucentis), and Novartis (Beovu), positioning itself as a cost-effective, regulatory-compliant alternative to unapproved pharmacy-compounded treatments. Originally founded in 2011 as Oncobiologics by the late Dr. Pankaj Mohan, the company is currently led by Chief Executive Officer Bob Jahr, who was appointed in July 2025 and brings over two decades of commercial leadership from Sobi and UCB Pharma. The executive team includes Lawrence A. Kenyon, who serves as Executive Vice President and Chief Financial Officer, and Laura Cantrell, who joined in January 2026 as Vice President of Corporate Strategy and Business Development following senior roles at Genentech and BeiGene. Governance is overseen by Chairman Faisal G. Sukhtian, an Executive Director at GMS Holdings, which remains the company’s largest stakeholder with a controlling interest of approximately 50.3%. The board also features Lead Independent Director Randy Thurman, a veteran healthcare executive with prior leadership experience at Rhone-Poulenc Rorer and VIASYS Healthcare.